ATE482710T1 - Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen - Google Patents

Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen

Info

Publication number
ATE482710T1
ATE482710T1 AT03719236T AT03719236T ATE482710T1 AT E482710 T1 ATE482710 T1 AT E482710T1 AT 03719236 T AT03719236 T AT 03719236T AT 03719236 T AT03719236 T AT 03719236T AT E482710 T1 ATE482710 T1 AT E482710T1
Authority
AT
Austria
Prior art keywords
cefditoren pivoxil
amorphous
absorption capacity
medical composition
oral absorption
Prior art date
Application number
AT03719236T
Other languages
English (en)
Inventor
Yukiko Yokoi
Shigeru Chikase
Hiroyuki Yamaguchi
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Application granted granted Critical
Publication of ATE482710T1 publication Critical patent/ATE482710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03719236T 2002-10-02 2003-04-28 Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen ATE482710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002290367 2002-10-02
PCT/JP2003/005461 WO2004030673A1 (ja) 2002-10-02 2003-04-28 経口吸収性が改善された抗菌性医薬組成物

Publications (1)

Publication Number Publication Date
ATE482710T1 true ATE482710T1 (de) 2010-10-15

Family

ID=32063766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719236T ATE482710T1 (de) 2002-10-02 2003-04-28 Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen

Country Status (13)

Country Link
US (1) US8648065B2 (de)
EP (1) EP1555024B1 (de)
KR (1) KR101019769B1 (de)
CN (1) CN1311831C (de)
AT (1) ATE482710T1 (de)
AU (1) AU2003235962A1 (de)
BR (1) BRPI0314932B8 (de)
CA (1) CA2500712C (de)
DE (1) DE60334391D1 (de)
ES (1) ES2358470T3 (de)
MX (1) MXPA05003357A (de)
PT (1) PT1555024E (de)
WO (1) WO2004030673A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379631T3 (es) * 2003-10-08 2012-04-30 Meiji Seika Pharma Co., Ltd. Composición antibacteriana no cristalina que contiene cefditoren pivoxilo
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
US20130143857A1 (en) * 2010-07-23 2013-06-06 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
CN101940575B (zh) * 2010-10-25 2012-05-30 石药集团欧意药业有限公司 一种头孢妥仑匹酯固体制剂及其制备方法
EP3177272A1 (de) * 2014-08-04 2017-06-14 Sandoz AG Wassergranulierungsverfahren für amorphe, schwer wasserlösliche arzneimittel
WO2016114727A1 (en) * 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
JPS60126230A (ja) * 1983-12-13 1985-07-05 Asahi Chem Ind Co Ltd 経口用β−ラクタム剤組成物
JPS60132918A (ja) * 1983-12-22 1985-07-16 Asahi Chem Ind Co Ltd 経口用セフアロスポリン組成物
JPS60188230A (ja) 1984-03-08 1985-09-25 Fujita Kikai:Kk 積層板の積み込み方法
JPS60188320A (ja) * 1984-03-08 1985-09-25 Asahi Chem Ind Co Ltd セフアロスポリン組成物
JPS62265226A (ja) * 1986-05-12 1987-11-18 Fujisawa Pharmaceut Co Ltd 経口投与用製剤
JPH01128926A (ja) * 1987-11-12 1989-05-22 Fujisawa Pharmaceut Co Ltd 経口投与用製剤
JPH0678234B2 (ja) 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0287588A (ja) 1988-09-24 1990-03-28 Murata Mfg Co Ltd 厚膜配線基板の抵抗体形成方法
JPH0364503A (ja) 1989-07-28 1991-03-19 Teijin Ltd 無塵衣
JPH0678234A (ja) 1992-08-07 1994-03-18 Sony Corp Ｆｍ復調器
JPH0717866A (ja) 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
AU4314196A (en) 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
AR004014A1 (es) 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
JP2831135B2 (ja) 1995-10-13 1998-12-02 明治製菓株式会社 経口投与用の抗菌性組成物
AU714735B2 (en) * 1996-09-20 2000-01-13 Meiji Seika Pharma Co., Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same
JPH1192780A (ja) 1997-09-18 1999-04-06 Mitsubishi Chemical Corp カカオ油脂の結晶転移抑制剤
PL194097B1 (pl) * 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania
JP3290970B2 (ja) 1998-07-22 2002-06-10 山之内製薬株式会社 難溶性ＮＳＡＩＤｓ含有固形製剤
TWI257311B (en) * 1998-07-28 2006-07-01 Takeda Chemical Industries Ltd Rapidly disintegrable solid preparation
JP2001131071A (ja) * 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd 非晶質および非晶質を含有する医薬組成物
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
ES2389179T3 (es) * 2001-04-26 2012-10-23 Meiji Seika Pharma Co., Ltd. Composición de cefditoren pivoxilo amorfo y procedimiento para producir el mismo
JP5051865B2 (ja) * 2001-05-29 2012-10-17 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド レシチンでのプロドラッグエステル非乳化調合物の経口バイオアベイラビリティの向上
US8440250B2 (en) 2008-02-08 2013-05-14 Fuji Oil Company, Limited Fat crystallization accelerator

Also Published As

Publication number Publication date
KR101019769B1 (ko) 2011-03-04
PT1555024E (pt) 2010-11-18
CN1694709A (zh) 2005-11-09
CA2500712C (en) 2011-08-09
DE60334391D1 (de) 2010-11-11
MXPA05003357A (es) 2005-06-22
BRPI0314932B8 (pt) 2021-05-25
US20060051411A1 (en) 2006-03-09
US8648065B2 (en) 2014-02-11
AU2003235962A1 (en) 2004-04-23
ES2358470T3 (es) 2011-05-11
BR0314932A (pt) 2005-08-02
WO2004030673A1 (ja) 2004-04-15
KR20050054993A (ko) 2005-06-10
EP1555024A1 (de) 2005-07-20
CN1311831C (zh) 2007-04-25
EP1555024B1 (de) 2010-09-29
EP1555024A4 (de) 2007-07-11
CA2500712A1 (en) 2004-04-15
BRPI0314932B1 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
JP4369623B2 (ja) 体液から治療上有効なタンパク質であるインターロイキン−１受容体拮抗薬を産生するための方法
DE69233413D1 (de) Ein physiologisch wirksames Polypeptid enthaltende pharmazeutische Zusammensetzung
CA2066403A1 (en) Transmucosal dosage form
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
KR910005885B1 (ko) 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제
ATE482710T1 (de) Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen
CN102579378B (zh) 小儿头孢地尼组合物冻干口腔崩解片及其制备方法
HRP20140590T1 (hr) Tekuä†i oblik g-csf konjugata
HK1055079A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
ATE172969T1 (de) Polyzyklische aromatische verbindungen, sie enthaltende pharmazeutische und kosmetische zusammensetzungen und deren verwendungen
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
DE60206871D1 (de) Pharmazeutische Formulierung enhaltend Midazolam zur buccalen Verabreichung
HK1055080A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
WO2001074396A8 (en) Composition and method for promoting oral health
JPH0570609B2 (de)
CN103301075A (zh) 一种头孢克肟组合物混悬颗粒剂及其制备方法
EA200101108A1 (ru) Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции
BRPI0608375A2 (pt) utilizacão de azitromicina, medicamento para o tratamento das conjuntivites bacterianas, processo de fabricacão de um medicamento de tratamento das infeccões oculares e acondicionamento para um medicamento para o tratamento das conjuntivites bacterianas
DE60112584D1 (de) Verfahren zur Herstellung einer flüssigen Dosierungseinheit und Kit
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
ATE420887T1 (de) Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi
AR046464A1 (es) Multiparticulas de liberacion controlada con mejoradores de la disolucion
WO2006066125A3 (en) Device and method for the vacuum infusion of a porous medical implant
CN202982637U (zh) 药品包装盒
RU2005480C1 (ru) Лекарственное средство

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties